Intelligent Bio Solutions Inc. (NASDAQ: INBS)

Sector: Healthcare Industry: Medical Devices CIK: 0001725430
Market Cap 3.67 Mn
P/B 0.33
P/E -0.32
P/S 0.83
ROIC (Qtr) -121.46
Div Yield % 0.00
Rev 1y % (Qtr) 30.81
Total Debt (Qtr) 1.92 Mn
Debt/Equity (Qtr) 0.17
Add ratio to table...

About

Intelligent Bio Solutions Inc., often recognized by its NASDAQ ticker symbol INBS, is a company that operates in the medical technology industry. Its primary business activities involve the development and commercialization of non-invasive diagnostic tests and screening solutions, with a global reach aimed at providing intelligent, pain-free, and accessible solutions to improve the quality of life. The company's main offerings include the Intelligent Fingerprinting Platform and the Biosensor Platform. The Intelligent Fingerprinting Platform is...

Read more

Investment thesis

Bull case

  • Operating cash flow of (9.38M) provides exceptional 230.63x coverage of minority interest expenses (40669), showing strong core operations.
  • Strong tangible asset base of 14.38M provides 7.47x coverage of total debt 1.92M, indicating robust asset backing and low credit risk.
  • Tangible assets of 14.38M provide robust 30.57x coverage of other current liabilities 470486, indicating strong asset backing.
  • Cash reserves of 740371 provide ample 18.44x coverage of acquisition spending 40158, enabling strategic growth opportunities.
  • Strong cash position of 740371 provides 1.57x coverage of other current liabilities 470486, indicating excellent liquidity.

Bear case

  • Investment activities of (321377) provide weak support for R&D spending of 1.95M, which is -0.16x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (9.38M) shows concerning coverage of stock compensation expenses of 97575, with a -96.13 ratio indicating potential earnings quality issues.
  • Free cash flow of (9.74M) provides weak coverage of capital expenditures of 361535, with a -26.94 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (11.21M) show weak coverage of depreciation charges of 1.19M, with a -9.43 ratio indicating high capital intensity and potential reinvestment needs.
  • Operating cash flow of (9.38M) barely covers operating expenses of 1.70M with a -5.53 ratio, suggesting thin operational efficiency margins and limited flexibility.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.22 2.13
EV to Cash from Ops. EV/CFO -0.42 2.75
EV to Debt EV to Debt 2.06 17.25
EV to EBIT EV/EBIT -0.35 2.89
EV to EBITDA EV/EBITDA -0.39 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF -0.41 29.36
EV to Market Cap EV to Market Cap 1.08 25.09
EV to Revenue EV/Rev 0.90 32.80
Price to Book Value [P/B] P/B 0.33 4.73
Price to Earnings [P/E] P/E -0.32 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Int. cover (Qtr) -131.60 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -108.15 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -66.98 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -6.11 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -6.01 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) -6.11 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) -5.58 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) 38.91 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) 5.21 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 24.81 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.25 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 0.14 1.80
Current Ratio Curr Ratio (Qtr) 2.38 4.18
Debt to Equity Ratio Debt/Equity (Qtr) 0.17 1.20
Interest Cover Ratio Int Coverage (Qtr) -131.60 196.93
Times Interest Earned Times Interest Earned (Qtr) -131.60 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -227.50 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) -254.49 -2,478.60
EBT Margin % EBT Margin % (Qtr) -256.43 -2,690.42
Gross Margin % Gross Margin % (Qtr) 56.30 30.80
Net Profit Margin % Net Margin % (Qtr) -256.40 -2,821.53